2μg (R: reducing condition, N:non-reducing condition).
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | BH3 interacting domain death agonist |
| Accession | P55957 |
| Amino Acid Sequence | Met1-Asp195 with His Tag at the C-Terminus |
| Expression System | E.coli |
| Molecular Weight | 15-25kDa (Reducing) |
| Purity | >95% by SDS-PAGE |
| Conjugation | Unconjugated |
| Tag | His Tag |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, pH7.4, 5% trehalose |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage |
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference | 1.Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. Genes Dev. 1996 Nov 15;10(22):2859-69. |
Background
BID (BH3 Interacting Domain Death Agonist) is a critical BH3-only pro-apoptotic protein containing an unstructured N-terminal domain and a conserved C-terminal BH3 domain. Upon cleavage by caspase-8, BID generates the active fragment tBID, which subsequently activates Bax/Bak and induces mitochondrial outer membrane permeabilization. Serving as an essential bridge between the death receptor and mitochondrial pathways, BID not only mediates apoptosis but also participates in hematopoietic homeostasis, tumor suppression, and mitochondrial structural maintenance. Aberrant BID expression is closely associated with various diseases: in tumors, its downregulation inhibits apoptosis and promotes drug resistance; during SARS-CoV-2 infection, the virus modulates BID to balance host cell survival and death; moreover, abnormal expression of BID alternative splicing isoforms is significantly correlated with the progression and poor prognosis of malignancies such as colorectal cancer, establishing BID as a potential diagnostic biomarker and therapeutic target.
Picture
Picture
SDS-PAGE
ELISA
Immobilized BID His Tag Protein, Human (Cat. No. UA016067) at 10.0μg/mL (100μL/well) can bind Biotinylated Bcl-x/BCL2L1 His Tag Protein, Human (Cat. No. UA011326) with EC50 of 3.51-4.23 ng/mL.
Immobilized BID His Tag Protein, Human (Cat. No. UA016067) at 10.0μg/mL (100μL/well) can bind Biotinylated Bcl-x/BCL2L1 Protein, Human (Cat. No. UA011327) with EC50 of 4.56-7.53 ng/mL.
